To the Editor: In their recent research paper, Isbister and colleagues questioned the clinical value of the CSL snake venom detection kit (sVDK) and the current approved dosing recommendations for CSL tiger snake antivenom (TSAV).1
The full article is accessible to AMA
members and paid subscribers.
Login to MJA or subscribe now.
- 1. Isbister GK, O’Leary MA, Elliott M, Brown SG. Tiger snake (Notechis spp) envenoming: Australian Snakebite Project (ASP-13). Med J Aust 2012; 197: 173-177. <MJA full text>
- 2. Steuten J, Winkel K, Carroll T, et al. The molecular basis of cross-reactivity in the Australian Snake Venom Detection Kit (SVDK). Toxicon 2007; 50: 1041-1052.
- 3. CSL. Snake Venom Detection Kit product information. February 2007. http://www.csl.com.au/docs/92/398/SVDK_Product_Leaflet,0.pdf (accessed Feb 2013).
- 4. CSL. Tiger snake antivenom product information. 21 January 2010. https://www.ebs.tga.gov.au/ebs/picmi/picmirepository.nsf/pdf?OpenAgent&id=CP-2010-PI-05203-3 (accessed Feb 2013).
- 5. White J. CSL antivenom handbook. Melbourne: CSL, 2001: 38. http://www.toxinology.com/generic_static_files/cslavh_antivenom_tiger.html (accessed Feb 2013).
Online responses are no longer available. Please refer to our instructions for authors page for more information.
No relevant disclosures.